β-Epoxyabiraterone acetate
| Chemical Name | β-Epoxyabiraterone acetate |
|---|---|
| Alternate Names | Abiraterone Acetate Impurities, Impurities of Abiraterone Acetate |
| CAT No. | CS-O-14343 |
| CAS Registry# | Not Available |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 407.55 g/mol |
| Mol. For. | C₂₆H₃₃NO₃ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Abiraterone Acetate |
| Purity | 95% |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CC(O[C@H](CC1=CC[C@@]([H])([C@@]2(C[C@@]3([C@]4(O3)C5=CC=CN=C5)[H])[H])[C@@]6(CC[C@@]24C)[H])CC[C@@]16C)=O |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
β-Epoxyabiraterone acetate is a new and emerging drug that has shown promising results in the treatment of prostate cancer. It is a derivative of abiraterone acetate, which is an FDA approved medication for the treatment of metastatic castration-resistant prostate cancer. β-Epoxyabiraterone acetate is a potent and selective inhibitor of CYP17A1, which is an enzyme involved in the production of androgens. This inhibition results in a decrease in the levels of androgens, which are known to stimulate the growth of prostate cancer cells.
Chemically, β-Epoxyabiraterone acetate is a white to off-white powder that is soluble in organic solvents such as methanol and ethanol. Its molecular formula is C26H33NO4 and its molecular weight is 435.54 g/mol. The drug is administered orally in the form of tablets and is rapidly absorbed into the bloodstream. Its half-life is approximately 3-4 hours and it is primarily metabolized by the liver.
The usage of β-Epoxyabiraterone acetate is still under investigation, but early clinical trials have shown promising results in the treatment of metastatic castration-resistant prostate cancer. The drug has been shown to be effective in patients who have failed other treatment options, including abiraterone acetate and chemotherapy. However, further clinical trials are needed to fully understand its potential benefits and risks.
Get an Instant Quote
Related Compounds
Abiraterone acetate reduced impurity | Abiraterone Acetate Dimer | Abiraterone Acetate-5,6-Epoxide | Beta-Epoxyabiraterone acetate | N-Nitroso Abiraterone Acetate | Abiraterone Acetate Diastereomer |